49802-71-3

Basic information

• Product Name: Benzeneacetyl chloride, a-cyclohexyl-
• CAS NO: 49802-71-3
• Molecular Formula: C14H17ClO
• Molecular Weight: 236.741
• Mol File: 49802-71-3.mol
• Article Data: 12

Chemical Properties

• CAS DataBase Reference: Benzeneacetyl chloride, a-cyclohexyl-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzeneacetyl chloride, a-cyclohexyl-(49802-71-3)
• EPA Substance Registry System: Benzeneacetyl chloride, a-cyclohexyl-(49802-71-3)

Safety Data

• Hazardous Substances Data: 49802-71-3(Hazardous Substances Data)

Upstream product

• 140-29-4 phenylacetonitrile 
• 953-91-3 cyclohexyl tosylate 
• 3894-09-5 2-cyclohexyl-2-phenylacetic acid 
• 103-82-2 phenylacetic acid 
• 3893-23-0 cyclohexyl phenyl acetonitrile 

Downstream Products

• 108619-75-6 cyclohexyl-phenyl-acetic acid tetrahydrothiopyran-4-yl ester 
• 99553-43-2 cyclohexyl-phenyl-acetic acid-(2-pyrrolidino-ethyl ester) 
• 22173-05-3 cyclohexyl-phenyl-acetic acid-(2-dimethylamino-ethyl ester) 
• 40797-11-3 (+/-)cyclohexyl-phenyl-acetic acid tropane-3endo-yl ester 
• 102288-64-2 Cyclohexyl-phenyl-thioessigsaeure-S-(2-diethylamino-ethylester) 
• 71570-27-9 Chlormethyl-d,l-α-cyclohexylphenylacetat 
• 102821-85-2 α-cyclohexylidenebenzyl phenyl ketone 
• 102821-86-3 α-cyclohexylidenebenzyl 4-chlorophenyl ketone 
• 5664-22-2 (+/-)-2-cyclohexyl-2-phenylacetaldehyde 
• 897445-81-7 2-(cyclohexyl-phenyl-methyl)-1H-benzoimidazol-4-ylamine 

Relevant articles and documents

Discovery of new C3aR ligands. Part 2: Amino-piperidine derivatives

The synthesis and structure-activity relationships against the C3a receptor of a series of substituted aminopiperidine derivatives are reported. DMPK properties and functional activities of selected compounds are described. The compounds obtained are the first non-arginine ligands of C3aR.

Synthesis and biological evaluation of benzimidazole derivatives as potent AMP-activated protein kinase activators

Design, synthesis and structure-activity relationships of benzimidazole derivatives as activators of the AMP-activated protein kinase (AMPK) are presented in this paper. AMPK is the central component of a protein kinase cascade that plays a key role in the regulation of energy balance. Once activated, AMPK initiates a series of responses that are aimed at restoring the energy balance of the cell and recent studies have indicated that AMPK plays an important role in regulation of the whole-body energy metabolism. The following study based on the lead compound S27847 involved modification of three regions of this compound. Preliminary structure-activity relationships are being described.

Pharmacological studies and synthesis of morpholino alkyl derivatives

Seven morpholin derivatives were synthesized (compounds 1-7) and their behavioural effects were evaluated; the elements considered were locomotor activity, motor coordination, catalepsy, stereotyped behaviour and antinociception. All the compounds, at doses of 10-20-40 mg/kg/i.p., induced a reduction of all behavioural elements without a significant antinociceptive effect. These results indicate that these morpholin derivatives affect the central nervous system.